|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||1.52 - 1.69|
|52 Week Range||1.04 - 10.29|
|Beta (3Y Monthly)||-16.47|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
(“AXIM® Biotech” or “AXIM”) (AXIM), a world leader in cannabinoid research and development, today announced that it has received a manufacturing license from the Dutch Ministry of Health, Welfare and Sports for the production, according to Good Manufacturing Practices (“GMP”), of the company’s pharmaceutical products to be used in clinical trials. Effective Oct. 1, 2018, the license allows AXIM to produce its cannabinoid-based pharmaceutical drug candidates for use in human clinical trials for multiple indications.
NEW YORK, Sept. 13, 2018-- AXIM ® Biotechnologies, Inc., a world leader in cannabinoid research and development, today announced that it has signed a Letter of Intent with Impression Healthcare Limited, ...
NEW YORK, Aug. 27, 2018-- AXIM ® Biotechnologies, Inc., a world leader in cannabinoid research and development, today announced that it has signed an exclusive distribution and license agreement with Revive ...
AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in cannabinoid research and development, today announced that the Company will be attending and presenting at BIT’s 16th Annual Congress of International Drug Discovery Science and Technology-2018 (IDDST-2018), a conference focused on updating the breaking research of drug discovery and development for academic and industrial professionals, taking place in Cambridge, Mass. from August 16-19, 2018. AXIM’s Chief Technology Officer, Lekhram Changoer, will bring his expertise to this year’s event as a presenter on the topic of “Novel cGMP Technologies for Extraction, Purification, and Conversion of Cannabinoids for the Pharmaceutical Industry.” His presentation is scheduled to take place on Friday, August 17 from 3:30-3:50 p.m. ET in the Discovery Room, 3rd Floor as part of the Other Enabled Technologies for Drug Discovery session.
AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in cannabinoid research and development, today announced positive results from stability and dissolution tests performed on its prime drug candidate, MedChew Rx®, which will undergo clinical trials for the treatment of pain and spasticity in Multiple Sclerosis (MS) patients. Results showed that the primary Active Pharmaceutical Ingredients (APIs) in MedChew Rx™ remained stable throughout the test and that the availability of the APIs was greater than 90%. MedChew Rx® is comprised of the cannabinoid molecules delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which generally degrade after time.
SAN DIEGO , Feb. 28, 2018 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States , announced that its major investment company AXIM® ...
Alternate Health Begins Beta Testing of FlorPass Patient Management Software System in Key Market
SAN ANTONIO , Dec. 11, 2017 /PRNewswire/ -- Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTCQB:AHGIF), an international, vertically-integrated medical cannabis ...
Alternate Health's Investor Webcast And Presentation Now Available For On-Demand Viewing At VirtualInvestorConferences.com
CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing why Medical Marijuana Inc. represents a compelling ...